As of 2025-03-18, the Relative Valuation of Madrigal Pharmaceuticals Inc (MDGL) is (667.82) USD. This relative valuation is based on P/E multiples. With the latest stock price at 342.44 USD, the upside of Madrigal Pharmaceuticals Inc based on Relative Valuation is -295.0%.
The range of the Relative Valuation is (588.70) - (734.29) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 27.9x - 41.7x | 34.8x |
| Forward P/E multiples | 22.2x - 34.8x | 28.5x |
| Fair Price | (588.70) - (734.29) | (667.82) |
| Upside | -271.9% - -314.4% | -295.0% |
| Date | P/E |
| 2025-03-17 | -16.18 |
| 2025-03-14 | -16.51 |
| 2025-03-13 | -15.31 |
| 2025-03-12 | -15.51 |
| 2025-03-11 | -15.90 |
| 2025-03-10 | -15.60 |
| 2025-03-07 | -15.71 |
| 2025-03-06 | -15.58 |
| 2025-03-05 | -16.46 |
| 2025-03-04 | -15.23 |
| 2025-03-03 | -14.86 |
| 2025-02-28 | -16.17 |
| 2025-02-27 | -15.91 |
| 2025-02-26 | -16.87 |
| 2025-02-25 | -14.67 |
| 2025-02-24 | -15.27 |
| 2025-02-21 | -15.93 |
| 2025-02-20 | -16.64 |
| 2025-02-19 | -16.29 |
| 2025-02-18 | -16.11 |
| 2025-02-14 | -15.98 |
| 2025-02-13 | -16.67 |
| 2025-02-12 | -16.12 |
| 2025-02-11 | -15.72 |
| 2025-02-10 | -16.00 |
| 2025-02-07 | -15.77 |
| 2025-02-06 | -15.65 |
| 2025-02-05 | -16.11 |
| 2025-02-04 | -15.31 |
| 2025-02-03 | -15.42 |
| 2025-01-31 | -15.87 |
| 2025-01-30 | -16.03 |
| 2025-01-29 | -15.47 |
| 2025-01-28 | -15.51 |
| 2025-01-27 | -14.74 |
| 2025-01-24 | -15.55 |
| 2025-01-23 | -16.12 |
| 2025-01-22 | -15.39 |
| 2025-01-21 | -14.55 |
| 2025-01-17 | -13.92 |
| 2025-01-16 | -12.93 |
| 2025-01-15 | -13.01 |
| 2025-01-14 | -12.99 |
| 2025-01-13 | -14.39 |
| 2025-01-10 | -16.06 |
| 2025-01-08 | -15.80 |
| 2025-01-07 | -15.32 |
| 2025-01-06 | -15.20 |
| 2025-01-03 | -15.15 |
| 2025-01-02 | -14.87 |